Colorectal Cancer in the Coming Years: What Can We Expect?
|
|
- Flora Poole
- 5 years ago
- Views:
Transcription
1 Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States
2 What Are the Key Questions? CONCEPT 1 - Novel oncogenic targets CONCEPT 2 - Targeting tumor evolution CONCEPT 3 - Multi-OMICS: Integration of genomic, transcriptomic, immune and stromal data
3 Understanding Colorectal Cancer Comprehensive Analysis of Genome Data Cancer Genome Atlas Network. Nature. 2012;487(7407): Walther A, et al. Nat Rev Cancer. 2009;9(7):
4 Novel Targets HER2 HERACLES Project HER2 amplification, RAS wildtype Trastuzumab + lapatinib 78% disease control Sartore-Bianchi A, et al. Lancet Oncol. 2016;17(6): Siena S, et al. J Clin Oncol. 2015;33(suppl): Abstract 3508.
5 Improving Targeted Therapies in mcrc CONCEPT 1 - Novel oncogenic targets CONCEPT 2 - Targeting tumor evolution CONCEPT 3 - Multi-OMICS: Integration of genomic, transcriptomic, immune and stromal data
6 Tumor Spatial Heterogeneity Inter-patient variation Intra-patient variation Intra-tumor variation Gerlinger M, et al. N Engl J Med. 2012;366(10):
7 Improving Targeted Therapy in mcrc PAST Single gene single marker single drug Companion Diagnostics 1 test alteration A 1 drug PRESENT Multi gene multi marker multi drug FUTURE Multi OMICS systems biomedicine adaptive (immune) drug mcrc, metastatic colorectal cancer
8 Improving Targeted Therapy in mcrc PAST Single gene single marker single drug Companion Diagnostics 1 test alteration A 1 drug PRESENT Multi gene multi marker multi drug FUTURE Multi OMICS systems biomedicine adaptive (immune) drug mcrc, metastatic colorectal cancer
9 Kopetz S, et al. J Clin Oncol. 2015;33(34): Progression-free survival (PFS) 2.1 months Response rate 5%
10 Dynamics of BRAF Inhibition Alpelisib Panitumumab EGFR RAS sos grb2 PI3K PiP2 PiP3 Encorafenib MEK BRAF EGFR upregulation following BRAF inhibition AKT mtor ERK Prahallad A, et al. Nature. 2012;483(7387): Corcoran RB, et al. Cancer Discov. 2012;2(3): Misale S, et al. Sci Transl Med. 2014;6(224):224ra26.
11 SINGLE DOUBLET From Single Targeting to Multi Targeting: Increasing Clinical Benefit in BRAF+ mcrc Vemurafenib + Panitumumab 3 13% Yaeger et al CCR 15 Vemurafenib + Cetuximab 4 20% Tabernero et al ASCO 14 Encorafenib + Cetuximab 5 22% Tabernero et al ESMO 16 Dabrafenib + Panitumumab 6 10% Atreya, ASCO 15 TRIPLET Response Rate Vemurafenib 1 5% Kopetz, JCO 15 Dabrafenib 2 11% Falchook, Lancet 08 Vemurafenib (BRAFi) + Cetuximab + Irinotecan 7 35% Hong, ASCO 15 Dabrafenib (BRAFi) + Panitumumab + Trametinib (MEKi) 6 26% Atreya, ASCO 15 Encorafenib (BRAFi) + Cetuximab + PI3Ki 5 32% Tabernero, ESMO 16 BEACON TRIAL: Encorafenib (BRAFi)+ 48% Cetuximab + Binimetinib (MEKi) 8,9 (+31% SD) Kopetz, ESMO 17 VanCutsem, ASCO-GI `18 Greater efficacy SD, stable disease 1. Kopetz S, et al. J Clin Oncol. 2015;33(34): Falchook et al. Lancet Yaeger R, et al. Clin Cancer Res. 2015;21(6): Tabernero J, et al. J Clin Oncol. 2014;32(5s): Abstract Tabernero J, et al. Ann Oncol. 2016;27(suppl_2): Abstract O Atreya CE, et al. J Clin Oncol. 2015;33(suppl): Abstract Hong DS, et al. J Clin Oncol. 2015;33(suppl): Abstract Huijberts S, et al. Ann Oncol. 2017;28(Suppl 5): Abstract 517P. 9. Van Cutsem E, et al. J Clin Oncol. 2018;36(4S): Abstract 627.
12 BEACON Trial Schema Patients with BRAF V600E -mutant mcrc Safety Lead-In Completed Binimetinib + encorafenib + cetuximab Dosedetermining cohort n = 9 Dose expansion cohort n = 21 Randomization 1:1:1 Phase III Currently Enrolling Triplet Therapy: Binimetinib + encorafenib + cetuximab n = 205 Doublet Therapy: Encorafenib + cetuximab n = 205 Control Arm: FOLFIRI + cetuximab or irinotecan + cetuximab n = 205 Disease progression Disease progression Disease progression Continued follow-up for evaluation of OS National Institutes of Health. Accessed May 1, Huijberts S, et al. Ann Oncol. 2017;28(Suppl 5): Abstract 517P. Van Cutsem E, et al. J Clin Oncol. 2018;36(4S): Abstract 627.
13 BEACON Trial: Safety Lead-In Efficacy 1 Previous regimen 2 Previous regimens Van Cutsem E, et al. J Clin Oncol. 2018;36(4S): Abstract 627.
14 Temporal Heterogeneity: Clonal Dynamics KRAS KRAS wt Basal RAS-wt tumor wt KRAS Response to anti-egfr treatment wt RAS-mutant tumor at progression to treatment Anti-EGFR treatment wt, wildtype
15 Clonal Dynamics in mcrc Patients Treated With Anti-EGFR mab in mcrc CT, computed tomography; mab, monoclonal antibody; PR, partial response Van Emburgh BO, et al. Nat Commun. 2016;7:13665.
16 Acquired Resistance to Anti-EGFR Therapy in CRC 2. Mutations in extracellular domain of EGFR Cell membrane S492R G465R/E G464L K467T I491M EGFR HER2 ampl MET ampl PI3-K AKT KRAS NRAS BRAF MEK 1. Downstream mutations or activation of alternative receptors that converge in MEK activation ERK Yonesaka K, et al. Sci Transl Med. 2011;3(99):99ra86. Montagut C, et al. Nat Med. 2012;18(2): Misale S, et al. Nature. 2012;486(7404): Diaz LA Jr, et al. Nature. 2012;486(7404): Bardelli A, et al. Cancer Discov. 2013;3(6): Troiani T, et al. Clin Cancer Res. 2013;19(24): Misale S, et al. Sci Transl Med. 2014;6(224):224ra26. Hobor S, et al. Clin Cancer Res. 2014;20(24): Arena S, et al. Clin Cancer Res. 2015;21(9): Siravegna G, et al. Nat Med. 2015;21(7): Russo M, et al. Cancer Discov. 2016;6(2):
17 Liquid Biopsy to Guide Biomarker-Based Treatment After Cetuximab/Panitumumab: Ongoing Trials Liquid biopsy Basal RAS wt tumor First-line chemo + anti- EGFR PD Biomarker Treatment Clinical Trial HER2 ampl Trastuzumab + lapatinib Heracles trial (phase II) BRAF mut BRAFi + antiegfr+ MEKi BEACON study RAS mut Rechallenge CHRONOS; FIRE-4 EGFR ECD ctdna genotyping - Panitumumab - 2 nd generation antiegfr: Sym004 PAN-HER NCT (phase II) NCT (phase I)
18 Cetuximab Rechallenge Mutations in RAS emerge during anti-egfr treatment RAS RAS wt wt RAS wt Basal RAS wt tumor Response to treatment Progression to treatment
19 Cetuximab Rechallenge Mutations in RAS emerge during anti-egfr treatment and decline when treatment is suspended RAS RAS wt wt RAS wt Basal RAS wt tumor Response to treatment Progression to treatment Off treatment
20 Liquid Biopsy for Longitudinal Monitoring of RAS Mutations in Blood of Patients: Rechallenge with Cetuximab Siravegna G, et al. Nat Med. 2015;21(7):
21 Ongoing Clinical Trials Evaluating Anti-EGFR Rechallenge in mcrc Study (Study ID) Anti-EGFR Agent or Combination Main Selection Criteria CRICKET (NT ) Cetuximab RAS and BRAF wildtype First-line irinotecan-based (FOLFIRI or FOLFOXIRI) cetuximab-containing therapy producing at least a PR REGAIN (NCT ) Cetuximab + irinotecan RAS and BRAF wildtype First-line chemotherapy regimen with a fluoropyrimidine and irinotecan (FOLFIRI) + cetuximab with initial PR/complete response (CR) and progressive disease (PD) with PD >6 weeks after the last administration of cetuximab FIRE-4 (EudraCT ) Cetuximab RAS wildtype First-line FOLFIRI + cetuximab therapy producing at least a PR A phase II Trial of Rechallenge With Panitumumab Driven by RAS Clonal- Mediated Dynamic of Resistance: CHRONOS (EudraCT ) Panitumumab RAS and BRAF wildtype First-line anti-egfr-containing therapy producing at least a PR Predefined criteria of RAS mutational load measured on plasma ctdna at progression of firstline and before rechallenge
22 PAST Single gene single marker single drug PRESENT Multi gene multi marker multi drug Co-ocurring alterations spatial heterogenity Clonal selection temporal heterogenity FUTURE Multi OMICS systems biomedicine adaptive immune / stromal drug
23 The Consensus Molecular Subtype (CMS) Classification Gene Expression CMS1 MSI Immune CMS2 Canonical CMS3 Metabolic CMS4 Mesenchymal 14% 37% 13% 23% MSI, CIMP high, hypermutation SCNA high Mixed MSI status, SCNA low, CIMP low SCNA high BRAF mutations KRAS mutations Immune infiltration and activation WNT and MYC activation Metabolic deregulation Stromal infiltration, TGFb activation, angiogenesis Worse survival after relapse Worse relapse-free and overall survival CIMP, cytosine-guanosine (CpG) island methylation phenotype; MSI, microsatellite instability Guinney J, et al. Nat Med. 2015;21(11):
24 FIRE-3: PFS and OS According to CMS in RAS Wildtype Accross All Treatment Groups PFS and OS according to CMS in RAS wild-type<br />across all treatment groups Probability of PFS P<.0001 Probability of Survival P<.0001 Months Since Randomization Months Since Randomization Stintzing S, et al. J Clin Oncol. 2017;35(Suppl 4): Abstract 3510.
25 Immunotherapy in mcrc Checkmate-142: Nivolumab + Ipilimumab in MSI-H PFS, % OS, % Andre T, et al. J Clin Oncol. 2018;36(suppl 4S): Abstract 553.
26 Is There Role for Immunotherapy in 95% of CRC Tumors That Are MSS? Can we convert noninflamed tumors to become inflamed? Inflamed Immune Excluded Immune Desert MSI-H (3% to 5%) CD8+ T cells infiltrated, but nonfunctional MSS (>95% of mcrc) CD8+ T cells accumulated, but not efficiently infiltrated CD8+ T cells absent from tumor and periphery Accelerate or remove brakes on T cell response Bring T cells in contact with cancer cells Increase number of antigen-specific T cells or increase antigen presentation MSS, microsatellite stable Kim JM, et al. Ann Oncol. 2016;27(8): Hegde PS, et al. Clin Cancer Res. 2016;22(8):
27 Combination Approaches for MSS CRC: PD-L1 + MEK Inhibitor PFS OS Patients Median (95% CI) 6-Month Median (95% CI) 6-Month 12-Month All (n = 84) 1.9 months (1.8, 2.3) 18% 9.8 months (6.2, 14.1) 65% 43% MSS (n = 42) a 2.5 months (1.8, 3.7) 27% 13.0 months (6.0, 25.8) 71% 51% KRAS mutant (n = 57) b 2.0 months (1.8, 2.3) 22% 9.5 months (6.0, 17.6) 67% 44% KRAS wildtype (n = 25) b 1.8 months (1.8, 2.6) 9% 10.0 months (4.9, 17.1) 65% 43% Data cutoff: September 4, a Of the remaining 42 non-mss patients, 32 patients had unknown MSI status, 9 patients were MSI-low and 1 patient was MSI-high. b 2 patients had unknown KRAS mutation status. Bendell J, et al. J Clin Oncol. 2018;36(suppl 4S): Abstract 560.
28 Phase III Trial of Cobimetinib and Atezolizumab in Chemotherapy-Refractory mcrc (COTEZO/IMblaze370) Patients with unresectable locally advanced or metastatic CRC (received at least 2 chemotherapy regimens)* N = 360 R 2:1:1 Atezolizumab + cobimetinib Atezolizumab Regorafenib Primary endpoint: OS Secondary endpoints: PFS, CR, PR, DOR, HRQoL (EORTC QLQ-C30) Stratified by tumor extended RAS status and time since diagnosis of first metastasis MSI-H capped at approximately 5%; 95% MSS At least 180 patients with extended RAS-mutant tumors to be enrolled PD PD PD *Experienced disease progression or was intolerant to at least two systemic chemotherapy regimens including fluroropyrimidines, irinotecan, or oxaliplatin DOR, duration of response; HRQoL, health-related quality of life; OS, overall survival National Institutes of Health. Accessed 8 February Accrual completed
29 Take-Home Messages - RAS, BRAF, and MSI are crucial to make clinical decisions in mcrc - Novel molecular targets are being evaluated with promising results (HER2) - Exciting results are emerging for BRAF mutant tumors - Novel therapeutic strategies should take into consideration heterogeneity and clonal dynamics - Novel therapeutic strategies should integrate immune and stromal factors - Immunotherapy is an excellent option for patients with MSI-H tumors - For MSS CRC tumors, novel strategies are promising
30 Thanks
31
Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationReview of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux
Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationLiquid biopsies to track clonal evolution and resistance to EGFR inhibition in mcrc
Liquid biopsies to track clonal evolution and resistance to EGFR inhibition in mcrc Alberto Bardelli Candiolo Cancer Center IRCCs University of Torino - Medical School Disclosures Horizon discovery Biocartis
More informationDaniele Santini University Campus Bio-Medico Rome, Italy
Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit
More informationNovel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer. Objectives
Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer Michael S. Lee, MD Assistant Professor of Medicine University of North Carolina Objectives Discuss important clinicopathologic
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationColon Cancer: State of the Art
Colon Cancer: State of the Art Heinz-Josef Lenz Professor of Medicine and Preventive Medicine Associate Director, Clinical Research J Terrence Lanni Chair in Cancer Research Co-Director, USC Center for
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationArray BioPharma Jefferies 2016 Global Healthcare Conference. June 9, 2016
Array BioPharma Jefferies 216 Global Healthcare Conference June 9, 216 Safe Harbor Statement 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationAbetter understanding of the tumor biology of colorectal cancer has led to. Beyond the second line
Beyond the second line of the care continuum in metastatic colorectal cancer In first-line treatment, a deep response on the tumor load is the primary aim to improve patient prognosis; however, in later
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationThe role of liquid biopsies in the treatment of advanced colon cancer
The role of liquid biopsies in the treatment of advanced colon cancer Clara Montagut Hospital del Mar, Barcelona ESMO CRC Preceptorship Valencia, May 12, 2017 1 ESMO consensus guidelines for the management
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationRight Drug for the Right Colorectal Patient: Select the Best Initial Therapy and What Comes After 5-FU/OXALI/IRINO?
Right Drug for the Right Colorectal Patient: Select the Best Initial Therapy and What Comes After 5-FU/OXALI/IRINO? Axel Grothey Professor of Oncology Minnesota -> Tennessee The Luxury of So Many Options...
More informationEric Van Cutsem University Hospitals Leuven, Belgium
BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti Epidermal Growth Factor Receptor Antibody Cetuximab for BRAF V600E Metastatic Colorectal
More informationColon Cancer ASCO Poster Review
Rome, February 11 th 2017 AIOM POST ASCO GI Review Colon Cancer ASCO Poster Review Lisa Salvatore UOC Oncologia Policlinico GB Rossi Azienda Ospedaliero Universitaria Integrata di Verona Me Before Me After
More informationCarcinoma colorettale: personalizzazione del trattamento
33 Incontro Oncologico del Triveneto Padova, Aprile 2017 Carcinoma colorettale: personalizzazione del trattamento Fotios Loupakis, MD PhD U.O.C. Oncologia Medica 1 Dipartimento di Oncologia Clinica e Sperimentale
More informationKeynote Presentation I New Era of CRC Management: Impact of Tumor Sidedness and Molecular Subtypes of CRC
Keynote Presentation I New Era of CRC Management: Impact of Tumor Sidedness and Molecular Subtypes of CRC Scott Kopetz, MD, PhD, FACP University of Texas MD Anderson Cancer Center Houston, Texas, United
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationHow to treat a patient with metastatic CRC? Towards personalized treatment strategies
How to treat a patient with metastatic CRC? Towards personalized treatment strategies Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Progress in the treatment
More informationESMO GI / BEACON CRC SAFETY LEAD-IN ENCORE PRESENTATION June 23, 2018
ESMO GI / BEACON CRC SAFETY LEAD-IN ENCORE PRESENTATION June 23, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationAxel Grothey West Cancer Center University of Tennessee, Germantown, TN, USA
Updated Results of the BEACON CRC Safety Lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mcrc) Axel Grothey West Cancer Center University
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationColon cancer: ASCO poster review. Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome
Colon cancer: ASCO poster review Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome a.destefano@istitutotumori.na.it 255 poster examined: my selection Clinical Practice Translational &
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationReview of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups. Chemotherapy and targeted agents in 1st line
ESMO Preceptorship Programme Colorectal Cancer Valencia, 18th May 2018 Review of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups Chemotherapy and targeted agents
More informationHeavilyTreated mcrc..whats next?
ESMO Preceptorship Programme Gastrointestinal Cancer 20-22 October 2016,Singapore Dr Surendra Pal Chaudhary Dept of Medical Oncology Dr BR Ambedkar Instituite Rotary Cancer Hospital All India Institute
More informationRAS and BRAF in metastatic colorectal cancer management
Review Article RAS and BRAF in metastatic colorectal cancer management Jun Gong 1, May Cho 1, Marwan Fakih 2 1 Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA; 2 Medical
More informationArray BioPharma Third Quarter of F2018 Update MAY 9, 2018
Array BioPharma Third Quarter of F2018 Update MAY 9, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationFighting a Smarter War On Colon Cancer:
Fighting a Smarter War On Colon Cancer: Value as a new endpoint? John L. Marshall, MD Tel: (202) 444-0275 Fax: (202) 444-1229 http://lombardi.georgetown.edu/gi Stakeholder Motivation Stakeholders FDA CMS/Payers
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationThe ESMO consensus conference on metastatic colorectal cancer
ESMO Preceptorship Programme Colorectal cancer Prague July, 6-7 2016 The ESMO consensus conference on metastatic colorectal cancer Andres Cervantes ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationNew therapeutic strategies for BRAF mutant colorectal cancers
Review Article New therapeutic strategies for BRAF mutant colorectal cancers Ryan B. Corcoran 1,2 1 Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA; 2 Department of Medicine, Harvard
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationTargets & therapies for colorectal cancer
Targets & therapies for colorectal cancer Jan Schellens Werkgroep "MOLECULAIRE DIAGNOSTIEK IN DE PATHOLOGIE 31-01-2014 Current treatment options for advanced colorectal cancer (CRC) First line: - CAPOX
More informationImmunoterapia en Cáncer colorrectal. Manuel Benavides
Immunoterapia en Cáncer colorrectal Manuel Benavides Agenda - Cáncer colorrectal / MSI - MSI-H / MSI-L o MSI-S - Inhibidores de Checkpoints Molecular Pathways in Colorectal Cancer tability or MSI (15%)
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationCOLORECTAL CANCER: STATE OF THE ART
COLORECTAL CANCER: STATE OF THE ART Andrés Cervantes Professor of Medicine DECLARATION OF INTERESTS Consulting and advisory services, speaking or writing engagements, public presentations Merck Serono
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationADVANCES IN COLON CANCER
ADVANCES IN COLON CANCER Peter T. Silberstein, M.D., FACP Professor, Creighton University Chief Hematology/Oncology UNIVERSAL SCREENING FOR LYNCH SYNDROME OF ALL PATIENTS WITH COLON CANCER ADOPTED BY CHI
More informationLa strategia terapeutica per il trattamento del carcinoma del colon-retto metastatico
VI Corso Nazionale Eventi Formativi AIOM-SIAPEC Roma,15 Giugno 2016 La strategia terapeutica per il trattamento del carcinoma del colon-retto metastatico Francesco Di Costanzo Direttore SC Oncologia Medica
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationREVIEW ON THE ESMO CONSENSUS CONFERENCE ON ADVANCED COLORECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 REVIEW ON THE ESMO CONSENSUS CONFERENCE ON ADVANCED COLORECTAL CANCER Andrés Cervantes Professor of Medicine Strategic changes
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationPanitumumab: The KRAS Story. Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd
Panitumumab: The KRAS Story Chrissie Fletcher, MSc. BSc. CStat. CSci. Director Biostatistics, Amgen Ltd Clinical Background: panitumumab in mcrc Panitumumab is a fully human IgG2 monoclonal antibody directed
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationTreatment of Advanced Colorectal Cancer
Treatment of Advanced Colorectal Cancer Alexis D. Leal, M.D. Assistant Professor, GI Medical Oncology University of Colorado Cancer Center Disclosures None Objectives Review the basics of advanced colorectal
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationCombination Approaches in Melanoma: A Balancing Act
Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic
More informationArray BioPharma. October 30, > First Quarter F2019 Update
Array BioPharma October 30, 2018 > First Quarter F2019 Update 1 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationHow I Treat Metastatic Colorectal Cancer
September 2018 Volume 16, Issue 9, Supplement 18 How I Treat Metastatic Colorectal Cancer Tanios Bekaii-Saab, MD Professor, Mayo Clinic College of Medicine and Science Program Leader, GI Program Mayo Clinic
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More informationMetastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage. Dr Lee-Ann Jones
Metastatic Colorectal Cancer : The role of Personalised Medicine, Biomarkers and Early tumour shrinkage Dr Lee-Ann Jones Aim Metastatic Colorectal Cancer: Past: 5FU, oxaliplatin, irinotecan..blanket treatment
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationKRAS G13D mutation testing and anti-egfr therapy
KRAS G13D mutation testing and anti-egfr therapy KRAS G13D mutation and anti-egfr therapy Current data do not support a need to specifically identify this mutation for assessing anti-egfr eligibility in
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationMANAGEMENT OF ADVANCED COLORECTAL CANCER
MANAGEMENT OF ADVANCED COLORECTAL CANCER Alberto Sobrero IRCCS San Martino IST Genoa Italy Disclosures : Pfizer, Roche, Merck, Amgen, Celgene, Bayer, Sanofi, Nordic, Takeda,BMS, Syrtex, Servier outline
More informationRandomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) ASCO Annual Meeting 2017 Randomized trial of irinotecan and cetuximab with
More informationLa biopsia liquida dei tumori: il viaggio. Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome
La biopsia liquida dei tumori: il viaggio Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome Must Know Necessary Travel Tips There is lack of drugs to treat all the
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationPrognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Bruno Vincenzi Università Campus Bio-Medico di Roma
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients Bruno Vincenzi Università Campus Bio-Medico di Roma Colorectal cancer 3 rd most common cancer worldwide Approximately
More informationMarcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari Milo Frattini XII Congresso AIFEG Villa Cagnola - Gazzada Schianno (VA) 16/17.10.2014 APC β-catenina APC Met (p16) Models of
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationRECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER
RECONSIDERING THE BENEFIT OF INTERMITTENT VERSUS CONTINUOUS TREATMENT IN THE MAINTENANCE TREATMENT SETTING OF METASTATIC COLORECTAL CANCER SUNAKAWA, Y, 1 BEKAIISAAB, T, 2 AND STINTZING, S. 3 SELECTED HIGHLIGHTS
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer Jefferies 2015 Healthcare Conference Ron Squarer, Chief Executive Officer November 19, 2015 Safe Harbor Statement Forward-looking statements
More information